Use of the adenoviral E2 late promoter

Details Use of the adenoviral E2 late promoter Use of the adenoviral E2 late promoter

2002-10-15

2009-08-11

Chen, Shin-Lin (Department: 1632)

Chemistry: molecular biology and microbiology

Process of mutation, cell fusion, or genetic modification

Introduction of a polynucleotide molecule into or...

C435S320100, C514S04400A, C536S023100, C536S024100

Reexamination Certificate

active

07572633

ABSTRACT:
The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter. The invention also relates to the uses of said nucleic acid construct.

REFERENCES:
patent: 5994132 (1999-11-01), Chamberlain et al.
patent: WO 97/16547 (1997-05-01), None
Deonarain, M., 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Verma et al., Sep. 1997, Nature, vol. 389, pp. 239-242.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Lowenstein et al., 2002, Current Opinion in Molecular Therapeutics, vol. 4, No. 4, p. 359-371.
Kodama et al., 2006, Current Medicinal Chemistry, vol. 13, p. 2155-2161.
Gorecki, D., 2001, Expert Opin. Emerging Drugs, 6(2): 187-198.
Rudinger, 1976, Peptide Hormones, Parsons, University Park Press, Baltimore, p. 1-7.
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
Bhat et al., 1987, EMBO Journal, vol. 6, No. 7, p. 2045-2051.
Gopalakrishna Bhat et al., In vivo identification of multiple promoter domains of adenovirus E11A-late promoter, The EMBO Journal, 6(7): 2045-2052 (1987).
Per S. Holm et al., YB-1 Relocates to the Nucleus in Adenovirus-infected Cells and Facilitates Viral Replication by Inducing E2 Gene Expression through the E2 Late Promoter, The Journal of Biological Chemistry, 277(12), 10427-1034 (2002).
Koji Koike et al., Nuclear translocation of the Y-box binding protein by ultraviolet irradiation, FEBS Letters, 417, 390-394 (1997).
Michael Ladomery et al., A role for Y-box proteins in cell proliferation, BioEssays, 17(1), ICSU Press, 9-11 (1995).
S. Swaminathan et al., Regulation of Adenovirus E2 Transcription Unit, Lucie Cancel Center, Northwestern University Medical School, 177-194 (1995).
Takefumi Ohga et al., Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene, The Journal of Biological Chemistry, 273 (11), 5997-6000, (1998).
Takefumi Ohga et al., Role of the Human Y Body-binding Protein YB-1 in Cellular Sensitivity to the DNA-damaging Agents Cisplatin, Mitomycin C, and Ultraviolet Light, Cancer Research 56, 4224-4228, (1996).

Affiliated with

Also associated with

Rating

Use of the adenoviral E2 late promoter does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of the adenoviral E2 late promoter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the adenoviral E2 late promoter will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4133401